Dr. Thusanth Thuraisingam

Dermatologist, Montreal, QC

Dr. Thusanth Thuraisingam obtained his Bachelor of Science in Honours in Immunology at McGill University before joining the PhD program at the McGill University Health Center under the supervision of Dr. Danuta Radzioch. His PhD research involved studies of the signalling pathways important to immune system regulation of cutaneous wound healing. He then went on to complete his medical studies at the University of Montreal before returning to McGill for his dermatology residency. During residency, he had developed an interest in hair disorders and worked with several prominent hair specialists around the world. After completing his residency, he pursued fellowship training in procedural dermatology at McGill University and a research fellowship in Melanoma at the university of Pittsburgh. He has published over 20 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national, and international meetings. He is the founding director of hair and scalp disorder clinic at JGH. As an assistant professor of dermatology at McGill, he enjoys teaching medical student and residents. He practices dermatology in both Montreal and Ottawa with a particular interest in hair disorders and surgical dermatology.

2:05 PM - 2:35 PM

FRI Apr 19

Reviewing the latest advancements in the treatment landscape for advanced cutaneous squamous cell carcinoma

This will be a case-based, interactive discussion with Dr. Claveau.

Learning Objectives:

  1. Strategies for optimizing the recognition and diagnosis of advanced Cutaneous Squamous Cell Carcinomas (cSCCs), along with the optimal referral pathways
  2. Examine the importance of a multi-disciplinary management of patients with advanced Cutaneous Squamous Cell Carcinoma, emphasizing its critical role in enhancing patient outeomes
  3. Discuss the critical role of anti-PD-L1 therapy in the comprehensive management of complex Cutaneous Squamous Cell Carcinoma cases, focusing on its efficacy, safety profile, and impact on patient outcomes.